Why Promising Drugs Struggle After FDA Approval: Understanding the Barriers to Market Success
For most drug developers, FDA approval feels like the finish line. Then launch day arrives and the real test begins.FDA approval confirms that a drug has met the applicable regulatory requirements for ...
Analog Selection in Pharma Forecasting: Getting It Right and Getting It Wrong
Every pharma forecast eventually leans on a comparison. Somewhere in the model there is a line that says, in effect, “our product will behave roughly like that one.” That product is the analog, and th ...
Which TPP Attributes Actually Matter? A Sensitivity-Driven Approach to Optimization
A Target Product Profile usually arrives as a table: indication, line of therapy, efficacy target, safety expectations, dosing, route of administration, positioning. Every row looks equally reasonable ...
Treatment Pathway Mapping: Uncovering Hidden Unmet Need in Real-World Care
Background: A mid-size pharmaceutical company was preparing to advance a late-stage asset in a chronic, specialist-led disease area. Epidemiological modeling pointed to a sizable addressable populati ...
Pharma Launch Forecasting: From Static Annual Models to Real-Time Commercial Intelligence
Background: A global specialty pharmaceutical company was approaching the launch of a new chronic-therapy asset in a market characterized by heavy competition. The compound had strong clinical differ ...
Evidence Without Context: Why Advanced Analytics Still Miss Commercial Reality
Advanced analytics has transformed how life sciences teams generate evidence. We can analyze massive datasets, model future markets, and simulate treatment pathways with remarkable precision. Yet desp ...